STAT+: NIH fails to disclose enough details about drug licensing, watchdog report finds
Amid increasing debate over the cost of prescription drugs, a federal watchdog agency found the National Institutes of Health does not consider whether a medicine it discovered and licensed to a pharmaceutical company may later be affordable, and also fails to provide enough information about its licensing activities to assess patient access.
The failure to consider the impact that licensing has on public health, especially at a time when a growing number of Americans say they cannot afford their medicines, prompted the Government Accountability Office to recommend that the NIH do a better job of disclosing licensing data and pay more attention to the potential for anti-competitive practices that affect drug pricing.
Continue to STAT+ to read the full story…
